Clinical trial
Pregabalin Epilepsy Add-On Trial
NCT00141258 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00141258 |
|---|---|
| Title | Pregabalin Epilepsy Add-On Trial |
| Official title | Pregabalin Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Partial Seizures |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Partial Seizures |
| Intervention type | Drug |
| Interventions | pregabalin |
| Enrollment | 178 |
| Start date | Oct 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Sep 1, 2005 |
| Last update posted | Jan 22, 2021 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: